Amicus price target raised to $21 from $20 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Amicus (FOLD) to $21 from $20 and keeps an Overweight rating on the shares following the Q3 beat. The firm says both the company’s Pompe and Fabry disease franchises have “significant levers that could be used to generate a steady stream of revenue growth.” It is a buyer on the stock into 2025.